Beyond the approval count: what an innovation landscape can tell us

Clarus Biotech Review

A defined FDA approval cohort can reveal the shape of innovation. It cannot rank clinical value or predict the next development program.

## Executive perspective

An approval count is a useful starting point for an industry discussion because it describes a clear regulatory event. Its meaning changes when the reader switches silently between new active ingredients, new formulations, biosimilars, additional indications, and products reviewed by different centers. This white paper uses a deliberately bounded annual cohort and proposes a repeatable method for turning that cohort into development questions.

The Clarus interpretation is that portfolio planning should begin with a classification discipline. A promising category deserves investigation, but the number of products reaching approval does not establish that another candidate in the category has a strong mechanism, a feasible trial, or a compelling patient benefit.

## Published evidence and scope

FDA’s CDER annual report records 50 novel drug approvals in 2024; 24 were first-in-class and 26 had orphan designation. The latter categories overlap and must not be added together. These figures concern the report’s novel-drug cohort, rather than all FDA product approvals. [1]

BioPharma Dive’s January 2025 coverage illustrates why the distinction matters: its year-end account discussed both novel medicines and new versions of existing therapies. The news lens is useful context; the regulatory report defines the statistical denominator here. [2]

## Clarus analysis: classify before comparing

A development team can use the cohort as a reference set, then make a separate record for each candidate under consideration. Record the disease setting, intended population, mechanism, route, comparator, and primary evidence question. The most useful comparison is a close clinical neighbor with a similar decision problem. A distant success in the same modality can illuminate possibilities while offering little information about this candidate’s actual risk.

First-in-class and orphan status should be treated as descriptors. They do not replace an assessment of the effect size, durability, tolerability, treatment burden, or remaining uncertainty. For internal planning, keep scientific novelty and patient importance in separate columns. A familiar mechanism with a meaningful usability improvement may deserve attention alongside a novel mechanism with a modest effect.

Approval activity also needs a time dimension. Compare like definitions across completed calendar years, and separate the date of approval from the date of commercial availability. A high annual total can coexist with difficult trial recruitment or uneven access to financing. These observations are compatible because they measure different stages of the development system.

## A practical landscape review

Assign one analyst to maintain the source cohort and another to check classification choices. Use the original regulatory record to resolve disputed dates and indications. For every summary slide, retain the denominator and a note on which product classes were excluded. This small discipline makes the figure auditable when the slide is reused in a board deck.

The review should end with decisions rather than a ranking of fashionable technologies. Identify which comparison changes a protocol assumption, which suggests a product-profile question, and which is simply background context. Keep a short change log so the team can tell whether a conclusion moved because of new evidence or because the comparison set changed.

## Limits and next evidence

This is a retrospective 2024 snapshot, not a live 2026 approvals dashboard. Counts do not measure unmet need addressed, incremental benefit, sales, or likelihood of success. The next useful evidence for an individual program is its own controlled clinical result and a justified comparator—not an extrapolation from the annual total.

Sources

https://www.fda.gov/media/184967/download

https://www.biopharmadive.com/news/fda-drug-approvals-end-2024-alyftrek-opdivo-qvantig-alhemo/736282/

Original article: https://www.clarusreview.bio/articles/approval-landscape-evidence-2024